Literature DB >> 27663543

Assessing the relationship between a body shape index and mortality in a group of middle-aged men.

Sen He1, Yi Zheng1, Hua Wang1, Xiaoping Chen2.   

Abstract

BACKGROUND & AIMS: Recently, a new anthropometric parameter emerged, namely A Body Shape Index (ABSI), which appears to be a major risk factor for mortality in the American and British populations. To the best of our knowledge, the relationship between ABSI and mortality was not studied previously in the middle-aged Chinese men. Therefore, we assessed the relationship based on a 15-year prospective study.
METHODS: In an urban community of Chengdu, 780 middle-aged Chinese men were included in 1992 and followed up for 15 years.
RESULTS: During the follow-up, 29 subjects died (mortality rate: 3.7%), and ABSI tended to be linearly associated with mortality. The subjects could be categorized into five groups by the quintiles of baseline ABSI, as follows: the first quintile (Q1), the second quintile (Q2), the third quintile (Q3), the fourth quintile (Q4) and the fifth quintile (Q5). Across the quintiles, the mortality rates were 3.8%, 5.3%, 3.0%, 4.7% and 1.9% in Q1, Q2, Q3, Q4 and Q5, respectively (ptrend = 0.386). With the highest quintile (Q5) as reference, univariate and multivariate Cox regression analyses presented that ABSI was not associated with mortality.
CONCLUSIONS: ABSI, a new anthropometric parameter, might not be associated with mortality in the middle-aged Chinese men. Further studies are needed to explore the specificities of ABSI in different populations.
Copyright © 2016 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  A body shape index; Anthropometric measures; Mortality

Mesh:

Substances:

Year:  2016        PMID: 27663543     DOI: 10.1016/j.clnu.2016.09.003

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  7 in total

1.  A Linear Relationship Between a Body Shape Index and Risk of Incident Type 2 Diabetes: A Secondary Analysis Based on a Retrospective Cohort Study in Japan.

Authors:  Wei Zhao; Jing-Jing Tong; Yong-Tong Cao; Jing-Hua Li
Journal:  Diabetes Metab Syndr Obes       Date:  2020-06-22       Impact factor: 3.168

2.  Utility of the Z-score of log-transformed A Body Shape Index (LBSIZ) in the assessment for sarcopenic obesity and cardiovascular disease risk in the United States.

Authors:  Wankyo Chung; Jung Hwan Park; Hye Soo Chung; Jae Myung Yu; Dong Sun Kim; Shinje Moon
Journal:  Sci Rep       Date:  2019-06-26       Impact factor: 4.379

3.  A body shape index in a small sample of Saudi adults with type 2 diabetes.

Authors:  Faisal Khalid A Zakri; Hassan Ali Abd El-Wahid; Mubarack Sani; Mohamed Salih Mahfouz
Journal:  J Family Med Prim Care       Date:  2019-10-31

4.  Body Roundness Index and Waist-Hip Ratio Result in Better Cardiovascular Disease Risk Stratification: Results From a Large Chinese Cross-Sectional Study.

Authors:  Ying Li; Yongmei He; Lin Yang; Qingqi Liu; Chao Li; Yaqin Wang; Pingting Yang; Jiangang Wang; Zhiheng Chen; Xin Huang
Journal:  Front Nutr       Date:  2022-03-10

5.  New metabolic health definition might not be a reliable predictor for mortality in the nonobese Chinese population.

Authors:  Ziqiong Wang; Yan He; Liying Li; Muxin Zhang; Haiyan Ruan; Ye Zhu; Xin Wei; Jiafu Wei; Xiaoping Chen; Sen He
Journal:  BMC Public Health       Date:  2022-08-29       Impact factor: 4.135

6.  Effectiveness of Z-score of log-transformed A Body Shape Index (LBSIZ) in predicting cardiovascular disease in Korea: the Korean Genome and Epidemiology Study.

Authors:  Shinje Moon; Jung Hwan Park; Ohk-Hyun Ryu; Wankyo Chung
Journal:  Sci Rep       Date:  2018-08-14       Impact factor: 4.379

7.  The disadvantage of morning blood pressure management in hypertensive patients.

Authors:  Kai Liu; Ying Xu; Shenzhen Gong; Jiangbo Li; Xinran Li; Runyu Ye; Hang Liao; Xiaoping Chen
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.